Brochure
10 Mar 2026
Next generation LNPs formulation with Curapath’s excipients
PDF 2.9 MB
Curapath and Certest have teamed up to develop next-generation Lipid Nanoparticle (LNP) formulations for nucleic acid-based therapeutics. This novel formulation combines Curapath's PEG-alternative shielding lipid with Certest's enhanced ionizable lipid, addressing challenges like immune-related side effects and reduced efficacy of PEG-based systems. This collaboration aims to improve stability, efficiency, and the versatility of payload delivery in advanced therapies.. Learn more about this cutting-edge combination of technologies by accessing the full document..
Content provided by our supplier
Curapath
-
Country/Region:Spain
-
On CPHI since:2023
-
Certificates:2
-
Employees:50 - 99
Company types
Primary activities
Other Content from Curapath (34)
-
Brochure Product Catalog
Discover Curapath's cutting-edge offerings in our catalog. Explore our LNP and PNP components, as well as our polymer conjugates, all designed to advance drug delivery. Enhance your research and development with our high-quality products.Advanced Polymer & Lipid Solutions for Non-Viral Drug DeliveryPEG-free excipients, transfection reagents, and polymer platforms for next-generation therapeutics -
Brochure Active Targeting Shielding Lipids for Targeted LNP Delivery
Targeted LNP Shielding Lipids (PEG-Free) | CliCr® Conjugation | CurapathEngineered PEG-free polysarcosine lipids modified with CliCr® conjugation technology to enable precise ligand attachment and extrahepatic LNP targeting.Explore our Active Targeting Shielding Lipids catalog, a curated selection of PEG-free polysarcosine lipids engineered for precise ligand conjugation and extrahepatic LNP delivery.
-
Brochure CDMO Services for Advanced Drug Delivery (LNPs, PNPs & Polymers)
From early formulation development to GMP manufacturing and aseptic Fill & Finish, supporting innovative therapeutics from preclinical to commercial supply.Explore Our Complete CDMO CapabilitiesExplore our CDMO Services overview, outlining our integrated approach to advanced lipid and polymer-based drug delivery, from early development to GMP manufacturing and aseptic Fill & Finish.
-
Brochure Formulation Development Packages for LNP & PNP
Curapath has launched a tiered suite of Formulation Development Packages to accelerate the design and optimization of Lipid Nanoparticle (LNP) and Polymer Nanoparticle (PNP) systems for nucleic acid and peptide delivery. These packages, Essential, Advanced, and Expert, are built to offer increasing levels of complexity, analytical depth, and formulation flexibility. -
Brochure Formulation Development Packages for PLA/PLGA Nanoparticles
Curapath introduces a structured suite of Formulation Development Packages, designed to streamline the creation and optimization of PLA/PLGA-based nanoparticles for the encapsulation of peptides and small molecules. -
Brochure Polymer-Drug Conjugates Case Study
A biotech company developing a polymer-drug conjugate (PDC) for parenteral use needed a partner to support their transition to clinical trials. They required expertise in process development, scale-up, and GMP-compliant manufacturing. Curapath met these needs with a comprehensive approach, ensuring efficiency and quality at every stage. Learn more about how Curapath met the needs of this client by accessing the full document.. -
Whitepaper Psar based solubilizing agent for second generation biologics
Our PolySarcosine based solution for biologics (Available for mAbs, recombinant vaccines, peptides, and hormones.) improves both Stability and Solubility outperforming current solutions like polysorbates without compromising safety. -
Brochure LNP Analytical Methods Application
Discover our cutting-edge capabilities for lipid nanoparticle characterization, alongside our meticulous in-process controls integrated into lipid nanoparticle formulations. Elevate your understanding of nanomedicine with our comprehensive insights. Download now to unlock the future of nanoparticle analysis. -
Brochure LNP Formulation & Process Development Application Note
LNP Formulation & Process Development Application Note! the sensitivity of LNPs for manufacturing and purification processes necessitates the development of a robust and scalable approach. This application note provides insight into Curapath's endeavor to achieve a GMP-compliant LNP formulation, demonstrating the critical path taken to ensure the production of clinically accepted drug products. Download now to understand the scalable manufacturing capabilities of Curapath. -
Brochure LNP Analytical Methods Application Note
Lipid Nanoparticle Formulation Characterization: Bridging the Gap from R&D to GMP Scale through Robust Analytical Excellence. -
Brochure Advanced Polymer Conjugation Technologies
Polymer conjugation technologies enabling tailored solutions for drug delivery, biologics, and medical devices from development to GMP manufacturing. -
Brochure Cys Bioconjugation Brochure
Optimized Methods Towards Site-selective Cysteine Specific Bioconjugations for Therapeutic Delivery. -
Brochure pSar White Paper
Polysarcosine (pSar)-a safer, more effective alternative to poly-ethylene glycol (PEG). -
Brochure Polymeric Nanoparticles Case Study
Development of a Highly Efficient, Biodegradable, Polymeric, Non-viral Vector (NVV) Platform for Nucleic Acid Delivery. -
Brochure Curapath-Knauer Application Note
Development, Screening and Optimization of LNP Formulations using the NanoScaler. -
Brochure pSar-VitE General Excipient Case Study
Development of PEG-free Excipients for Drug Delivery. -
Brochure Polysarcosine-Based Excipients for Advanced Drug Delivery
Access Curapath’s PSar-based solutions to improve stability, solubility, and performance in advanced drug delivery systems. -
Brochure Poly-L-Lysine-Based Excipients for Advanced Drug Delivery
Access Curapath’s Poly-L-Lysine-based solutions for enhanced delivery performance, functionalization, and advanced drug delivery applications. -
Brochure Poly-L-Glutamic Acid-Based Excipients for Advanced Drug Delivery
Access Curapath’s Poly-L-Glutamic Acid-based solutions for improved solubility, stability, and performance in drug delivery systems. -
Brochure Poly-L-Arginine-Based Excipients for Advanced Drug Delivery
Access Curapath’s Poly-L-Arginine-based solutions designed to enhance delivery performance and support advanced therapeutic applications. -
Brochure Poly-L-Ornithine-Based Excipients for Advanced Drug Delivery
Access Curapath’s Poly-L-Ornithine-based solutions for tailored drug delivery applications, enabling enhanced performance and formulation flexibility. -
Brochure LNP Formulation & Process Development for GMP Manufacturing
Explore LNP formulation, purification, and scalable manufacturing for mRNA delivery, from microfluidic mixing to GMP-ready production. -
Brochure NanoScaler Pro Application Note
Implementation of IJM NanoScaler Pro: Automated screening system for lipid nanoparticle formulation. -
Brochure Polymer-Drug Conjugates (Case Study)
Optimization, Scale-up, and GMP Manufacturing of a Polymer-Drug Conjugate for Parenteral Administration. -
Brochure Next generation Lipid Nanoparticle (LNPs) formulation
Certest and Curapath have joined forces to develop a novel LNP formulation leveraging the complementary Benefits of their proprietary excipients. -
Brochure PLGA/PLA API encapsulation
Scalable PLA/PLGA nanoparticle solutions for peptides and small molecules, with formulation, QC, and release studies for cost-effective drug delivery. -
Brochure Biologics Solubilizer
Discover our PSar-based solubilizing agent for improved biologic stability and solubility, offering a safe, scalable alternative to polysorbates. -
Brochure PEG-Free Shielding Lipids
Explore PEG-free shielding lipids that improve LNP stability, circulation, and targeting for more flexible and effective RNA delivery. -
Brochure Solutions For Active Targeting: Application Note
Explore how surface functionalization transforms LNPs into precise, receptor‑guided delivery systems for RNA therapeutics. -
Brochure Lung-Targeted LNP Development (Case Study)
Explore next-generation lung-targeted LNPs with PEG-free PSar shielding and CliCr® conjugation for efficient, selective pulmonary delivery. -
Brochure Active Targeting Shielding Lipids Catalog
Discover CliCr®-modified shielding lipids for enhanced functionalization, particle stability, and targeted delivery from R&D to GMP-ready scale. -
Brochure Featured Products
Discover Curapath's featured products catalog, a curated selection of advanced excipients and delivery components ready to accelerate your formulation programs. -
Brochure Product Catalog 2026
Curapath offers high-quality LNP and PNP components, as well as polymer conjugates, designed to support advanced drug delivery research and development. -
Brochure CDMO Services
Curapath’s CDMO platform for advanced drug delivery, offering development, analytical services, GMP manufacturing, and sterile Fill & Finish.